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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the motor
neuromuscular system leading to complete paralysis and premature death. The multifactorial nature of ALS that
involves both cell-autonomous and non-cell-autonomous processes contributes to the lack of effective therapies,
usually targeted to a single pathogenic mechanism. RNS60, an experimental drug containing oxygenated
nanobubbles generated by modified Taylor-Couette-Poiseuille flow with elevated oxygen pressure, has shown
anti-inflammatory and neuroprotective properties in different experimental paradigms. Since RNS60 interferes with
multiple cellular mechanisms known to be involved in ALS pathology, we evaluated its effect in in vitro and in vivo
models of ALS.
Methods: Co-cultures of primary microglia/spinal neurons exposed to LPS and astrocytes/spinal neurons from
SOD1G93A mice were used to examine the effect of RNS60 or normal saline (NS) on the selective motor neuron
degeneration. Transgenic SOD1G93A mice were treated with RNS60 or NS (300 μl/mouse intraperitoneally every
other day) starting at the disease onset and examined for disease progression as well as pathological and
biochemical alterations.
Results: RNS60 protected motor neurons in in vitro paradigms and slowed the disease progression of C57BL/6-
SOD1G93A mice through a significant protection of spinal motor neurons and neuromuscular junctions. This was
mediated by the (i) activation of an antioxidant response and generation of an anti-inflammatory environment in
the spinal cord; (ii) activation of the PI3K-Akt pro-survival pathway in the spinal cord and sciatic nerves; (iii) reduced
demyelination of the sciatic nerves; and (iv) elevation of peripheral CD4+/Foxp3+ T regulatory cell numbers. RNS60
did not show the same effects in 129Sv-SOD1G93A mice, which are unable to activate a protective immune
response.
Conclusion: RNS60 demonstrated significant therapeutic efficacy in C57BL/6-SOD1G93A mice by virtue of its effects
on multiple disease mechanisms in motor neurons, glial cells, and peripheral immune cells. These findings, together
with the excellent clinical safety profile, make RNS60 a promising candidate for ALS therapy and support further
studies to unravel its molecular mechanism of action. In addition, the differences in efficacy of RNS60 in SOD1G93A
mice of different strains may be relevant for identifying potential markers to predict efficacy in clinical trials.
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Background
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset
neurodegenerative disorder that affects the motor neuro-
muscular system leading to progressive muscle weakness,
paralysis and death by respiratory failure within 3–5 years
after diagnosis [1, 2]. Until now, only two therapeutic
agents, riluzole and edaravone, developed as potential anti-
glutamatergic and free radical scavenger respectively, have
been approved by the Food and Drug Administration
(FDA) for treatments aimed at slowing ALS disease pro-
gression. However, while riluzole marginally extends patient
life by 2–3 months [3, 4], edaravone so far has only shown
a slowing of the rate of decline of the ALSFRS-R score
compared with placebo in a small subset of ALS patients at
early disease stage [5]. This paucity of therapies is in part
due to the multifactorial nature of ALS pathogenesis that
involves both cell-autonomous and non-cell-autonomous
processes [6]. The cause of ALS remains unknown except
for the genetic forms that represent only about 15–20% of
all cases and are clinically indistinguishable from the
sporadic form of ALS. The affected genes are involved in
various cellular functions, suggesting a large variety of pos-
sible disease mechanisms. Although more than 20 different
genes have been linked to ALS [7], to date, the most reliable
and informative disease model is the transgenic mouse
overexpressing human superoxide dismutase 1 (hSOD1),
which recapitulates the main pathological traits of ALS [8].
Evidence from these mice and from ALS patients indicates
that multiple mechanisms are involved in the death of the
motor neurons (MNs) and the loss of muscular innerva-
tions. They include dysfunctions intrinsic to motor neurons
such as protein aggregation, impaired RNA processing and
metabolism, mitochondrial dysfunction, oxidative stress,
cytoskeletal alterations and impairment of axonal transport
[6, 9]. Other extrinsic mechanisms involve additional cell
types of the central nervous system (CNS) (such as reactive
astroglia and microglia) or the peripheral immune system
(like macrophages and T-cells) that may elicit neuroinflam-
matory processes contributing actively to motor neuron
degeneration [10–12]. Motor neurons become vulner-
able to these mechanisms in adult life, through the
loss of compensatory pro-survival mechanisms, creat-
ing a disbalance between the signaling pathways of
survival and death. Protective compensatory mechanisms
may include the activation of pro-survival pathways such as
the phosphatidylinositol-3 kinase (PI3K)-Akt pathway [13]
and/or the induction of an anti-inflammatory environment
[14]. It has been reported that neurotrophic factors, e.g.,
IGF1, GDNF and VEGF [15–17], are able to rescue motor
neurons in SOD1 mutant mice through activation of the
p-Akt pathway. On the other hand, a newly emerging
hypothesis states that adaptive immunity through Th2 cells
or and T regulatory cells (Treg cells) may initially activate
the protective function of microglia or macrophages in the
spinal cord, thereby providing a protective milieu to sustain
motor neuron viability. As the disease progresses, the decline
in Treg and the increase of Th1-mediated immunity lead to
a shift of the microglia/macrophages toward a more proin-
flammmatory phenotype, which accelerates motor neuron
degeneration [18]. Consistent with this hypothesis, we re-
cently demonstrated that in C57BL/6-SOD1G93A mice there
was a prominent immune response in the motor neurons
and sciatic nerves compared to a variant of the model in a
different genetic background (129Sv-SOD1G93A mice), and
this was associated with a slower disease progression rate,
preservation of myelin sheath morphology and a delayed
neuromuscular junction (NMJ) denervation in the C57BL/6
model [19–21]. Therefore, sustaining the initial compensa-
tory mechanisms, in addition to inhibiting the toxic mecha-
nisms, is likely to be the best strategy to significantly slow
down the disease progression in ALS.
RNS60 is a novel experimental drug containing oxygen-
filled charge-stabilized nanostructures (CSNs) generated
using modified Taylor-Couette-Poiseuille (TCP) flow under
elevated oxygen pressure [22]. CSNs consist of an oxygen
core surrounded by layers of positive and negative electrical
charges [23]. The biological effects of RNS60 have been at-
tributed to the physical properties of the CSNs, as a control
solution containing a similar level of oxygen as RNS60 (50–
60 ppm) and not subjected to TCP flow modification is not
biologically effective [22]. The putative mechanisms of action
of RNS60 encompass activation of pro-survival pathways, in-
crease in mitochondrial biogenesis, protection of myelin
forming cells, reduction of inflammation, and increase of
Tregs [22, 24]. For example, RNS60 attenuates the expres-
sion of pro-inflammatory molecules in activated mouse
microglia cells through the activation of the PI3-kinase-Akt
pathway [22]. Additional studies have shown that RNS60
protects dopaminergic neurons and improves motor func-
tion in a mouse model of Parkinson disease by activating the
pro-survival PI3K-Akt pathway and reducing microglial acti-
vation [23]. Moreover, it showed improvement of learning
and memory in a transgenic model of Alzheimer disease by
protecting hippocampal and cortical neurons, preventing tau
phosphorylation and upregulating neuronal plasticity [25,
26]. Another positive effect of RNS60 is its ability to increase
synaptic transmission by upregulating ATP synthesis in
mitochondria [27, 28] and decrease fatigability of nerve stim-
ulated muscles [29]. Finally, it is able to inhibit disease pro-
gression in multiple sclerosis rodent models by regulating
the immune responses and presumably by promoting myelin
maintenance and repair [24, 30–32].
Therefore, RNS60 seems to influence multiple cellular
mechanisms that are also involved in ALS pathology sug-
gesting that it may have a potential beneficial impact in this
disease as well. Accordingly, in the present study we investi-
gated the effect of RNS60 in both in vitro and in vivo
models of familial ALS linked to SOD1G93A mutation.
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Methods
Preparation of RNS60
RNS60 was generated at Revalesio (Tacoma, WA) using a
rotor/stator device that incorporates controlled turbulence
and Taylor-Couette-Poiseuille flow as described before
[22]. The resulting fluid was immediately placed into glass
bottles (KG-33 borosilicate glass, Kimble-Chase) and
sealed using gray chlorobutyl rubber stoppers (USP class
6, West Pharmaceuticals) to maintain pressure and
minimize leachables. When tested after 24 h, the oxygen
content was 55 ± 5 ppm. Chemically, RNS60 only contains
water, sodium chloride, and 50–60 ppm oxygen [22].
Normal saline (NS) from the same manufacturing batch
was used as control. For the first in vitro experiment on
motor neuron toxicity induced by LPS-activated
microglia, we used an additional control ONS60, which is
saline with a similar oxygen content as RNS60 (55 ±
5 ppm) but not processed with TCP flow. ONS60 con-
tacted the same device surfaces as RNS60 and was bottled
in the same way.
SOD1G93A mice
Transgenic animals (B6SJL-TgN SOD-1-SOD1.G93A-
1Gur) were originally obtained from Jackson labora-
tories (USA) and then maintained on a C57BL6/J or
129Sv background (following indicated as C57BL/6-
SOD1G93A or 129Sv-SOD1G93A, respectively) at the Mario
Negri Institute for Pharmacological Research, Milan, Italy
(IRFMN). The animals were housed under SPF (specific
pathogen free) standard conditions (22 ± 1 °C, 55 ± 10%
relative humidity and 12-h light/dark schedule), 3–4 per
cage, with free access to food (standard pellet, Altromin,
MT, Rieper) and water. Procedures involving animals and
their care were conducted in conformity with the institu-
tional guidelines of the Mario Negri Institute for Pharma-
cological Research, Milan, Italy IRFMN, which are in
compliance with national (D.lgs 26/2014; Authorization
n.19/2008-A issued March 6, 2008 by Ministry of Health)
and Mario Negri Institutional regulations and Policies
providing internal authorization for persons conducting
animal experiments (Quality Management System certifi-
cate—UNI EN ISO 9001:2008—reg. No. 6121); the NIH
Guide for the Care and Use of Laboratory Animals (2011
edition) and EU directives and guidelines (EEC Council
Directive 2010/63/UE). The Statement of Compliance
(Assurance) with the Public Health Service (PHS) Policy
on Human Care and Use of Laboratory Animals has been
newly reviewed (9/9/2014) and will expire on September
30, 2019 (animal Welfare Assurance #A5023-01).
Primary microglia-motor neuron co-cultures
Primary cells for the microglia/motor neuron co-cultures
were obtained from the spinal cord of 13-day-old C57BL/6J
mouse embryos as previously reported [33]. The viability of
motor neurons was assayed as previously described [33].
Only the SMI32-positive cells, with typical morphology tri-
angular shape, single well-defined axon, large bodies diameter
≥ 20 μm) and intact axons and dendrites were counted; this
number was normalized to the mean of SMI32-positive cells
counted in the appropriate control wells. After 6 days in vitro
were exposed to LPS for 24 h to induce the motor neuron
death. RNS60 10% v/v or NS were added 2 h before the LPS.
Primary astrocyte-spinal neuron co-cultures
Primary SOD1G93A and non-transgenic (NTG) astrocytes
were prepared as previously reported [13, 34, 35]. Briefly,
cortices of E13-E14 embryos from C57BL/6-SOD1G93A mice
or their NTG littermates were dissected and mechanically
dissociated in Hanks’ balanced salt solution (HBSS)
containing 33 mM glucose. After centrifugation, the
pellet was resuspended in culture medium (Dulbecco’s
modified Eagle’s medium/F12, 2 mM L-glutamine,
33 mM glucose, 5 lg/mL gentamycin, 10% horse serum]
and seeded (500,000 cells/mL) onto 48- or 6-well plates
coated with 1.5 μg/mL poly-L-ornithine. Repeated washing
with HBSS, 12 h of orbital shaking at 200 rpm and treatment
with 10 M AraC once they reached confluence, rendered
astrocyte cultures free of microglia, oligodendrocytes, and
neurons. SOD1G93A and non-transgenic co-cultures were
prepared as previously described [13, 35]. Spinal cords of
E13-E14 embryos were dissected and mechanically dissoci-
ated in HBSS, 33 mM glucose. The cells were centrifuged
onto a 4% bovine serum albumin cushion at 1000 rpm for
10 min and the pellet resuspended in neuron culture
medium: Neurobasal (Gibco, Rockville, MD, USA), 2 mM
L-glutamine, 33 mM glucose, 5 μg/mL gentamycin, 1 ng/mL
brain-derived neurotrophic factor, 25 μg/mL insulin, 10 μg/mL
putrescine, 30 nM sodium selenite, 2 μM progester-
one, 100 μg/mL apo-transferrin, 10% heat-inactivated
horse serum, and 10 uM AraC. Cells were seeded (1,000,000
cells/ml) onto 48-well plates with a pre-established astrocyte
confluent layer to obtain spinal neuron-cortical astrocyte co-
cultures. Non-transgenic and SOD1G93A co-culture were ob-
tained from non-transgenic and SOD1G93A neurons seeded
on non-transgenic and SOD1G93A astrocytes, respectively.
Motor neurons obtained from E13-14 embryos are fully dif-
ferentiated and express the specific transcription factors Hb9
and Islet-1/2. Few days after plating, they show adult charac-
teristics such as profuse dendrite and axon outgrowth and
synapse formation [36–38]. Co-cultures were treated twice
(DIV 0 and 3) with 10% v/v of RNS60 or normal saline
(NS) or oxygenated normal saline (ONS) as controls and
fixed at DIV 6.
Immunocytochemistry and evaluation of motor neuron
survival in astrocyte-spinal neuron co-cultures
Immunocytochemistry was run as previously described
[35, 39]. After blocking the non-specific binding sites by
Vallarola et al. Journal of Neuroinflammation  (2018) 15:65 Page 3 of 22
incubation with a solution containing 10% normal goat
serum (NGS) and Triton in PBS (phosphate-buffered sa-
line) 0.01 M, the cells were incubated with the primary
antibodies (overnight at 4 °C), diluted in a solution con-
taining 1% NGS and Triton in PBS 0.01 M. We used the
following primary antibodies: anti-SMI32 (1:1000,
Covance, Princeton, NJ, USA) and anti-NeuN (1:250,
Chemicon, Temecula, CA, USA). Cells were then washed
and incubated with the appropriate secondary fluorescent
antibody (1:500, Alexa Fluor Dyes, Life Technologies,
Grand Island, NY, USA) or secondary biotinylated antibody
(1:500, Vector Laboratories, Burlingame, CA, USA) for tyr-
amide signal amplification (TSA, Perkin Elmer) following
the manufacturer’s instructions. Images were acquired with
Olympus BX41 fluorescence microscope. Motor neuron
survival was evaluated as previously described [35, 39]. The
labeling with anti-SMI32 antibody highlights motor neu-
rons with typical morphology and large cell bodies (diam-
eter ≥ 20 μm) and anti-NeuN antibody was used to identify
all neurons in twelve adjacent frames per well at × 10 mag-
nification. Data were expressed as the ratio of the number
of motor neurons to the total neurons.
Neurite outgrowth evaluation
For morphological analysis, we used Image J software
(http://imagej.nih.gov/ij/) with the NeuronJ plug in [40].
Cells were visualized by SMI32 staining and analyzed for
the following parameters: total neurites extensions per
neuron and number of neurites per neuron. Neurites
were manually traced and measured on size-calibrated
images starting from the soma of motor neurons, 5 inde-
pendent experiments with each N = 15 motor neurons
each were analyzed per condition.
RNS60 mouse treatments
Female C57BL/6-SOD1G93A or 129Sv-SOD1G93A mice
were treated every other day by intraperitoneal (i.p.) in-
jection with 300 μl of RNS60 or Normal Saline (NS).
Treatments of SOD1G93A mice (22 mice per group)
started from the onset of the disease evaluated when the
body weight is at the peak level and the hind limbs show
first signs of tremors and reduced abduction but not im-
pairment in motor performance and muscle strength.
This occurs at 15 weeks of age in our mouse colony;
therefore, all mice start the treatment at 105 days. A set
of mice (8 per group) were sacrificed at 20 weeks of age
(symptomatic stage) for histopathological, biochemical
and molecular analysis. The rest of each group (n = 14)
were followed until the end stage to assess the effect on
survival. Treatment of 129Sv-SOD1G93A mice (10 mice
per group) started from the 13th week of age (onset of
the disease assessed as above) until 16 weeks of age
(symptomatic stage) when they were sacrificed for histo-
pathological, biochemical and molecular analysis.
Behavioral analysis, motor dysfunction assessment and
survival
Evaluation of disease was performed in all mice twice a
week from the onset of the disease, by the same investi-
gator blinded to the treatment. The grip strength test
was used to measure the limb resistance as previously
described [35]. Mice were placed on a horizontal metal-
lic grid which was then gently inverted. The latency to
fall of each mouse was recorded. The test ended after
90 s. In the case of failure, the measurement was
repeated three times and the best performance of the
session was considered for the statistical analysis. We
evaluated the onset of neuromuscular symptoms at the
age when the mouse exhibits the first failure in the paw
grip strength test at two consecutive time points. The
age at which the mice were no longer able to perform
the grip strength test was considered as time of paralysis.
The mice were euthanized by deep anesthesia when they
were unable to right themselves within 10 s after being
placed on either side. This time was considered the end
stage of the disease and was used to calculate the sur-
vival interval from onset.
Immunohistochemistry
Spinal cords were processed as previously described [35].
Briefly, under deep anesthesia, mice were transcardially per-
fused with PBS followed by 4% paraformaldehyde (PFA) so-
lution. The spinal cords were quickly removed, postfixed for
24 h, and cryopreserved in 30% sucrose solution at 4 °C until
they sank, included in Tissue-tek OCT (Sakura, Zoeter-
wounde, The Netherlands), frozen in n-pentane at − 45 °C
and stored at − 80 °C until analysis. Spinal cord immunohis-
tochemistry was performed on free floating sections (30 μm).
The number of motor neurons was determined on serial sec-
tions (20, one every ten) from lumbar spinal cord segments
L2-L5 of 3 mice per group as previously described [13]. The
sections were stained with cresyl violet to detect the Nissl
substance of neuronal cells. Motor neuron counting was per-
formed at × 10 magnification using the free software ImageJ
(http://imagej.nih.gov/ij/), previously calibrated. NISSL la-
beled neurons with clear nucleus and nucleolus and an area
of the cell body higher than 400 μm2 was identified as motor
neurons. The number of motor neurons was calculated for
each hemisection and the means used for statistical analysis.
Immunofluorescence was evaluated on 5–7 coronal spinal
cord slices (one every ten) from lumbar spinal cord per ani-
mal. The following primary antibodies and staining methods
were used: mouse anti-SMI-31 (1:1000, Sternberger Inc);
rabbit anti-Iba1 (1:1000, Wako); mouse anti-GFAP (1:2500,
Millipore); rat anti-CD68 (1:200, AbDSerotec); rabbit anti-
hSOD1 (1:1500, Upstate); rabbit anti-S100β (1:3000,
Sigma), and neurotrace conjugated with Alexa-647 (1:500,
Invitrogen). Appropriate fluoro-conjugated secondary
antibodies (1:500 dilution) were used: Alexa 549, Alexa
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647 and Alexa 488 (Alexa Fluor® Dyes, Life Technologies).
The sections were analyzed under Olympus Fluoview con-
focal microscope. The quantification of GFAP, CD68,
IBA1, and S100β intensity was carried out, by determining
the mean gray value of fluorescent signal in the ventral
horns in the relative surface occupied by the staining. The
quantification of SMI31 positive cell was evaluated consid-
ering the cells double stained with SMI31 and neurotrace
with a typical motor neuronal morphology. The quantifi-
cation of hSOD1 signal was evaluated by determining the
area fraction of fluorescent signal in the ventral horns of
lumbar spinal cord. All these analyses were carried out
using the free software ImageJ (http://imagej.nih.gov/ij/)
by the same operator blinded to treatment, by determin-
ing a threshold value within a gray-scale (corresponding
to the maximum level of an unstained section back-
ground) and considering as positive events all the pixels
falling over this value. The cellular distribution of p-Akt
was assessed by immunohistochemistry using the tyra-
mide amplification protocol as previously described [39].
Briefly, the endogenous peroxidases were inactivated by
1% hydrogen peroxide in TBS (0.1 M Tris-HCl, 0.14 M
NaCl, pH 7.4). The sections were then incubated with 3%
bovine serum albumin (BSA) in TBS/Triton 0.1% 1 h at
RT, and then probed overnight at 4 °C in 3% BSA, TBS/
Triton with an anti-p-Akt rabbit polyclonal antibody,
1:500 dilution, from Cell Signaling. Subsequently, the sec-
tions were washed in TBS/Triton and incubated 1 h at RT
in 1% BSA, TBS with a secondary biotinylated anti-rabbit
antibody, 1:200 dilution, from Vector. The secondary anti-
body was revealed with a TSA amplification kit, Cy5 (Per-
kin Elmer). The sections were then immunostained for
GFAP according to the protocols described above. For
each immunofluorescence procedure, some of the sections
were processed without primary antibody, to verify the
specificity of the staining.
Neuromuscular junctions (NMJs)
For detection of the NMJ denervation according to the
previously described protocol [35], tibialis anterior mus-
cles (TAM) were dissected and snap-frozen in isopen-
tane cooled in liquid nitrogen. Cryostat sections of
20 μm collected on poli-lysine objective slides (VWR
International) were fixed in chilled acetone for 10 min,
incubated in a blocking solution (0.3% Triton, 10% NGS
in 0.01 M PBS) for 1 h at 22 °C and left overnight at 4 °C
with anti-synaptophysin primary antibody (rabbit, 1:100,
Synaptic System) in 0.15% Triton, 5% NGS, 0.01 M PBS.
Then the sections were incubated with goat anti-rabbit
647 (1:500, Alexa Fluor® Dyes, Life Technologies) second-
ary antibody and with bungarotoxin (1:500, Invitrogen)
conjugated with Alexa Fluor® 594 (Life Technologies).
Innervated neuromuscular junctions were identified by la-
beling with bungarotoxin, totally or partially co-localized
with synaptophysin. Plaques marked with bungarotoxin
only were considered denervated and were expressed as
the percentage of the total plaques (counted in 8 adjacent
frames per section). Five sections, at 20X magnification,
were analyzed for each mouse. Tibialis anterior muscle
was also used to analyze the infiltration of CD68+ cells in
the vicinity of the NMJ using an antibody rat anti-CD68
(1:200, AbD Serotec) after the incubation in a blocking so-
lution (0.1% Triton, 10% NGS in 0.01 M PBS) for 1 h at
22 °C and left overnight at 4 °C with the primary antibody
in 0.1% Triton, 3% NGS, 0.01 M PBS. Fluorescence images
along the z-axis were taken by Olympus confocal micros-
copy using a 20X objective and z-stacking was performed
by using ImageJ/Fiji software (with Z-StackProjection/
SUM command; National Institutes of Health).
Western blot
Mice were sacrificed according to institutional ethical
procedures by decapitation, and the spinal cord and sci-
atic nerve were rapidly dissected. The spinal cord was
immediately frozen on dry ice and stored at − 80 °C. For
each mouse, the lumbar spinal cord was longitudinally
transected at 50 μm in a cryostat with ventral and dorsal
spinal cord sections as separate samples. The resulting
cryostat ventral material was homogenized by sonication
in ice-cold homogenization buffer (20 mM Tris-HCl
pH 7.4, 2% Triton X-100, 150 mM NaCl, 1 mM EDTA,
5 mM MgCl2, anhydrous glycerol 10%, protease and
phosphates inhibitor cocktail, Roche), centrifuged at
13000 rpm for 30 min at 4 °C, and the supernatants
were collected and stored at − 80 °C. The sciatic nerves
were processed as previously described [19]. Briefly, tis-
sues were powdered in liquid nitrogen, next homoge-
nized by sonication in ice-cold homogenization buffer
(20 mM Tris-HCl pH 7.4, 2% Triton X-100 1%, 150 mM
NaCl, 1 mM EDTA, 5 mM MgCl2, anhydrous glycerol
10%, protease and phosphates inhibitor cocktail, Roche)
and centrifuged at 13,000 rpm for 15 min at 4 °C. Equal
amounts of total protein homogenates were loaded on
polyacrylamide gels and electroblotted onto PVDF
membrane (Millipore) as previously described [35]. Blots
were first blocked with 5% BSA (Sigma) in TBS/Tween
0.1% for 1 h at room temperature and then over night at
4 °C with one of the following primary antibodies: rabbit
monoclonal anti-p-Akt (1:750, Cell Signaling), anti-Akt,
(1:1000, Cell Signaling), anti-p-GSK3β (1:1000 rabbit
polyclonal specific for phospho-Ser9 of GSK3β, Cell Sig-
naling), rat anti-MBP (1:1000 Chemicon), mouse anti
CNPase (1:1000 Chemicon), rabbit polyclonal anti-Nrf2
(1:200, Santa Cruz Biotechnology), mouse monoclonal anti-
GFAP (1:1000 millipore), mouse monoclonal anti β-actin
(1:15000 Chemicon), and mouse monoclonal anti-GAPDH
(1:20000, Millipore). Membranes were then washed and in-
cubated with horseradish peroxidase-conjugated anti-
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rabbit, anti-mouse or anti-rat secondary antibodies (Santa
Cruz) and developed by Luminata Forte Western Chemilu-
minescent horse radish peroxidase (HRP) Substrate (Milli-
pore) on the Chemi-Doc XRS system (Bio-Rad).
Densitometry analysis was performed with Quantity One
(Bio-Rad) software.
Dot blot analysis
Proteins (3 μg) were directly loaded onto nitrocellulose
Trans-Blot transfer 0.45 μm (Bio-Rad) membranes,
depositing each sample on the membrane by vacuum
filtration on a Bio-Dot Microfiltration Apparatus (Bio-
Rad), as described previously [41]. Dot blot membranes
were blocked with 3% (w/v) BSA (Sigma) and 0.1% (v/v)
Tween 20 in Tris-buffered saline, pH 7.5, incubated with
mouse monoclonal anti-NT (1:1000; Merck-Millipore),
then with anti-mouse peroxidase-conjugated secondary
antibody (Santa Cruz Biotechnology Inc.). Blots were de-
veloped with Luminata™ Forte Western Chemilumines-
cent HRP Substrate (Millipore) on the ChemiDoc XRS
system (Bio-Rad). Densitometry was done with Progenesis
PG240 v2006 software (Nonlinear Dynamics). NT immu-
noreactivity was normalized to the actual amount of pro-
teins loaded on each dot in the membrane as detected
after Ponceau Red staining (Fluka). Values were expressed
as mean ± SEM.
Real-time PCR
Tissues (spinal cords and spleen) were freshly col-
lected and immediately frozen on dry-ice. The ventral
portion of lumbar spinal cord and a segment of spleen
was homogenized, and total RNA from spinal cord was
extracted using the Trizol method (Invitrogen) and puri-
fied with PureLink RNA columns (Life Technologies).
RNA samples were treated with DNase I and reverse tran-
scription was performed with High Capacity cDNA
Reverse Transcription Kit (Life Technologies). Real-time
PCR was performed using the Taq Man Gene expression
assay (Applied Biosystems) following the manufacturer’s
instructions, on cDNA specimens in triplicate, using 1x
Universal PCR master mix (Life technologies) and 1x mix
containing specific receptors probes for the interleukin 1
beta (IL1β Mm00434228_m1), chemokine (C-C motif)
ligand 2 (CCL2, Mm00441242_m1), interleukin 4 (IL-4,
Mm00445259_m1), chitinase-like 3 (Ym1, Mm0065
7889_mH), forkhead box P3 (FoxP3, Mm00475162_m1),
and cluster of differentiation 4 (CD4, Mm00442754_m1)
(Life Technologies). Relative quantification was calculated
from the ratio between the cycle number (Ct) at which
the signal crossed a threshold set within the logarithmic
phase of the given gene and that of the reference β-actin
gene (4310881E; Life technologies). Mean values of the
triplicate results for each animal were used as individual
data for 2−ΔΔCt statistical analysis.
Statistical analysis
One-way or two-way ANOVA was used to compare differ-
ences between more than two groups, post hoc Fisher’s
least significant difference (LSD). Two-way ANOVA for re-
peated measures was used to compare the behavioral ana-
lysis. The Mantel-Cox log rank test was used for comparing
motor deficit onset, paralysis and survival between groups.
Results
RNS60 protects motor neurons in two different cellular
models of ALS
The effect of RNS60 was tested initially on motor
neuron/glia co-cultures derived from C57BL/6J mouse
embryos. The co-cultures were exposed to 1 μg/mL lipo-
polysaccharide (LPS) for 24 h after 6 days in vitro (DIV).
In this paradigm, co-treatment with LPS and 10% v/v of
normal saline (NS) reduced MN viability by about 30%
(72.12 ± 1.82% vs 100 ± 2.51% in untreated control
cultures). The toxic effect of LPS was significantly coun-
teracted by treatment with 10% v/v of RNS60 (94.23 ±
3.72%) (Fig. 1a–d). Cultures treated with ONS60, which
has an oxygen concentration similar to RNS60 but has
not been processed by TCP flow, did not show a differ-
ence compared to the NS conditions (Additional file 1:
Figure S1). Therefore, we decided to omit ONS60 in the
following experiments. Then, RNS60 was tested using an
in vitro model of ALS consisting of astrocyte/spinal
neuron co-cultures derived from C57BL/6J mouse
embryos expressing human SOD1G93A or NTG [35]
(Fig. 1e–g). In this paradigm, a spontaneous and se-
lective loss of large mutant motor neurons occurs
after 6 DIV when compared with non-transgenic cultures
under the same conditions [13, 35]. SOD1G93A and NTG
co-cultures were treated with 10% v/v of RNS60 or NS as
control, at DIV0 and DIV3. At 6 DIV, SMI32-positive MNs
were counted and the ratio of MNs to all NeuN-positive
neurons was calculated. While MN viability in the un-
treated co-cultures expressing SOD1G93A was only 55.38 ±
2.01% compared to the non-transgenic ones (NTG 100 ±
7.13%), it was significantly increased by treatment with
RNS60 (92.76 ± 9.84%), while control solution NS did not
modify MN survival (NS = 63.16 ± 4.70%) (Fig. 1i). Analysis
of neuritic outgrowth of the MNs revealed that RNS60 sig-
nificantly ameliorated the reduction of both the number
and total extension of neurites in SOD1G93A co-cultures,
compared to NS (Fig. 1j, k).
RNS60 delays neuromuscular impairment of
C57BL/6-SOD1G93A mice
Female C57BL/6-SOD1G93A mice were randomly divided
into two groups, one received NS and the other RNS60.
All mice were treated intraperitoneally (IP) with RNS60
or NS (300 μL/mouse) every other day starting at
105 days, corresponding to about 1 week before the
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onset of muscle strength loss as we have routinely ob-
served in these mice [42]. As shown in Fig. 2a, the
RNS60 treatment significantly extended the age of the
muscle strength impairment by 1 week (RNS60 128.8 ±
1.2 days, NS 121.3 ± 1.1 days, mean ± SEM, p < 0.0001).
The age at which the mice were no longer able to per-
form the test was considered as the time of paralysis.
Figure 2b shows that RNS60 treatment induced a signifi-
cant delay of paralysis by about 8 days (163.4 ± 1.4 days,
mean ± SEM) compared to NS (155.3 ± 2.5 days, mean ±
SEM, p = 0.009). Consistently, the mean survival age was
also extended by 10 days in RNS60-treated mice (175.1
± 2.8 days, mean ± SEM) compared to the NS-treated
group (164.7 ± 4.6 days, mean ± SEM), although this
difference was not statistically significant (p = 0.254)
(Fig. 2c). However, we observed that at the time when
50% (6/13) of mice treated with NS had died, more than
85% (12/14) of the mice treated with RNS60 were still
alive. Overall, the mean duration from symptoms
onset to end-stage sacrifice (survival interval) was
Fig. 1 RNS60 protects MNs from death in two cellular models of ALS. a–c Representative images of primary microglia-MN enriched co-cultures
exposed to LPS for 24 h after 6 DIV. e–h MNs were identified by morphology, intense SMI32 immunolabeling and diameter > 20 μm. d The bar graph
indicates that LPS reduces the viability of control (NS) treated MNs by about 30%. This toxic effect was significantly prevented by RNS60 (10% v/v). Data
are expressed as mean ± SEM (n = 6), One-way ANOVA (p < 0.001) followed by post hoc Fisher’s LSD. ***p < 0.001. e–h Representative images of
SMI32-(green) labeled MNs in NTG and C57BL/6-SOD1G93A co-cultures treated with NS or RNS60 (scale bar: 50 μm). Inserts show MNs with the neuritic
arbor at higher magnification (scale bar: 20 μm). i Quantitative assessment of MN survival in astrocyte-spinal neuron co-cultures from NTG (black) or
SOD1G93A (gray) co-cultures. Cells were treated with 10% v/v of RNS60 or NS, or left untreated as control. The columns show the number of viable
MNs (as a percentage of NTG untreated samples). Data are expressed as the ratio between the MN number (SMI32-positive, maximum diameter >
20 μm) and the number of total NeuN-positive neurons. Only treatment with RNS60 completely prevented MN loss in transgenic co-cultures. Data are
expressed as mean ± SEM (n = 5 independent experiment), Two-way ANOVA (p < 0.04) followed by post hoc Fisher’s LSD. j, k The analysis of the
neuritic outgrowth of the MNs revealed a reduction of number and total extensions of neurites in transgenic co-cultures. RNS60 was able to
significantly prevent the decrease of both parameters. Data are mean ± SEM (n = 5). Data were analyzed with two-way ANOVA followed by post hoc
Fisher’s LSD: *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = non-significant
Vallarola et al. Journal of Neuroinflammation  (2018) 15:65 Page 7 of 22
increased in mice treated with RNS60 by about 17%
(p = 0.048) (Fig. 2d).
RNS60 prevents degeneration and impairment of spinal
motor neurons and reduces the hSOD1 positive vacuoles
For the histopathological and biochemical analyses, a
separate set of female C57BL/6-SOD1G93A mice were
randomly divided into two groups (NS or RNS60); these
mice were sacrificed at 140 days of age corresponding to
80% muscle deficit of the untreated control group. A
group of NTG littermates were also sacrificed at
20 weeks of age. The MNs remaining in the lumbar
spinal cord of C57BL/6-SOD1G93A mice were counted,
and their viability was expressed as percentage of the
MNs counted in NTG mice. While in C57BL/6-
SOD1G93A mice treated with NS only 22.6 ± 1.7% of
MNs with a size > 400 μm2 were still present in the ven-
tral horn of lumbar spinal cord, in the RNS60-treated
mice, this number was significantly increased to more
than twice (46.93 ± 2.62%) (Fig. 3a–d). Not only was the
number of MNs higher, their function was protected too
as demonstrated in Fig. 3e–h. Under normal conditions,
phosphorylated neurofilament (NF) labeled with SMI31
antibody mostly stains the axons and neurites and is
lacking from the MN soma (Fig. 3e). In contrast, when
neurons become stressed or damaged, like in SOD1G93A
mice, phosphorylated NF strongly accumulates in the
cell body as well as in swelled axons and neurites
(Fig. 3f ). In mice treated with RNS60, this stress-
induced phenomenon appears clearly reduced com-
pared with NS-treated mice (Fig. 3g). By counting the
number of SMI31-positive substructures in MN somata
and swelled neurites, we observed a significant reduction
of these structures in RNS60-treated mice (30.1 ± 2.4%)
compared to mice treated with NS (43.3 ± 3.7%) (Fig. 3h).
Another common feature found in lumbar spinal cord
of transgenic mice is the accumulation of hSOD1,
which appears mainly confined to the membrane of
vacuoles formed by the swelling of mitochondria [43, 44].
While in C57BL/6-SOD1G93A mice treated with NS,
we clearly observed numerous hSOD immunoreactive
vacuoles in the lumbar spinal cord (Fig. 3j), their
numbers were significantly reduced in RNS60 treated
mice (Fig. 3k, l).
Fig. 2 RNS60 delays muscle weakness onset and paralysis and increases survival interval in C57BL/6-SOD1G93A mice. The treatment with RNS60
(300 μl/mouse/IP) every other day starting from the onset (hind limbs tremor and reduced abduction) a Kaplan-Meier curve showing the RNS60-
induced delay (7 days) of the onset of muscle weakness based on the initial failure in the paw grip strength test for two consecutive time points.
Log–rank Mantel–Cox test was done comparing NS (n = 21) vs RNS60 (n = 22) treated mice (p < 0.001). b Kaplan-Meier curve showing the RNS60-
induced delay (7 days) of muscle paralysis, considered as the age at which the mice were no longer able to perform the grip strength test. Data
were analyzed using the Log-rank test, p < 0.01. c Kaplan-Meier curve for survival showed an increase of about 10 days in mice treated with
RNS60 (175.1 ± 2.8 days, mean ± SEM, n = 14 mice) compared to NS (164.7 ± 4.6 days, mean ± SEM, n = 13 mice) for the time at which 50% of the
animals were euthanized. This increase was not statistically significant for the Log-rank test (p = 0.2544). d The survival interval, calculated from
the symptom onset until the time at which the mice were euthanized, was increased by 17% by RNS60 (70.1 ± 2.9 days, mean ± SEM) compared
to NS-treated mice (59.7 ± 4.6 days, mean ± SEM). The bar graph represents mean ± SEM. Difference between means was evaluated using non-
parametric Mann Whitney test (p = 0.048)
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RNS60 increases reactive gliosis and anti-inflammatory
cytokines in the lumbar spinal cord
Reactive astrocytosis evaluated by GFAP immunoreactiv-
ity as well as microgliosis are considered hallmarks of
neuroinflammation in the spinal cord of SOD1G93A mice
as they increase with the progression of the disease. In
fact, we observed an increased immunoreactivity for the
astroglial protein GFAP in the ventral horn of lumbar
spinal cord of C57BL/6-SOD1G93A mice treated with NS
with respect to NTG mice. Unexpectedly, the treatment
with RNS60 induced a slight but significant further
increase of the GFAP immunoreactivity (Fig. 4a–d). This
effect was less evident and not statistically significant
when we evaluated the GFAP levels in the homogenate
of the entire lumbar spinal cord by Western blot
(Additional file 2: Figure S2). In addition, we did not de-
tect changes in the levels of immunoreactivity for S100β, a
marker of aberrant astrocytes that promotes MN degener-
ation in SOD1G93A mice [45] (Additional file 3: Figure S3).
With respect to microglia, we observed a differential re-
sponse depending on the marker used to detect it. While
reactive microglia immunostained with IBA1, which is
high in C57BL/6-SOD1G93A mice, was not changed by
RNS60 treatment (Fig. 4e–h), macrophagic/phagocytic
microglia labeled with CD68 antibody was increased in
the ventral horn of lumbar spinal cord of RNS60 treated
mice as compared to NS-treated mice (Fig. 4i–k). The
relative quantification of the immune signal showed a
significant upregulation in RNS60- versus NS-treated
mice (Fig. 4l). When we measured transcript levels of
the pro-inflammatory markers CCL2 (Fig. 4m) and
IL-1β (Fig. 4n) in the ventral lumbar spinal cord of
C57BL/6-SOD1G93A mice, we found a significant in-
crease compared to NTG mice that was not different
between NS- and RNS60-treated mice. In contrast, the
anti-inflammatory cytokine IL-4 (Fig. 4o) was signifi-
cantly increased in RNS60-treated mice. Consistently,
the reduction of the M2 marker YM1 observed in
Fig. 3 RNS60 prevents MN dysfunction, loss and reduces the hSOD1-positive vacuoles in C57BL/6-SOD1G93A mice. a–c Representative images of
NISSL staining performed on LSC sections from NTG and C57BL/6-SOD1G93A mice treated with NS (SOD1G93A NS) or RNS60 (SOD1G93A RNS60) at
the symptomatic stage of the disease (140 days). Scale bar: 100 μm. d Quantification of motor neurons with cell body area > 400 μm2 in LSC. At
symptomatic stage of the disease, MNs were decreased in both transgenic groups of mice compared to NTG. Treatment with RNS60 displayed
significant neuroprotection (46.9 ± 2.62%) compared to SOD1G93A mice treated with NS (22.6% ± 1.7). The bar graph represents mean ± SEM as
percentage versus NTG controls (n = 3 animals per group). e–g RNS60 reduced the accumulation of phosphorylated neurofilaments (SMI31 green)
in the MN cell body (arrow) labeled with neurotrace (NT, red) and proximal axons (arrow head) which is an index of MN dysfunction (scale bar:
20 μm). h In transgenic mice, we observed a marked increase of SMI31-labeled MNs compared to NTG mice (8.9 ± 1.3%). RNS60 significantly
reduced the number of impaired MN (30.1 ± 2.4%) compared to NS-treated SOD1G93A mice (43.3 ± 3.7%). The bar graph represents mean ± SEM
(n = 3 mice per group). i–k Laser scanning confocal photomicrographs of hSOD1 staining (green) in LSC MNs of NTG and transgenic mice treated
with NS or RNS60 (scale bar: 20 μm). l Quantification showed the elevated level of hSOD1 immunoreactivity in transgenic LSC compared to NTG.
This effect was significantly reduced by the treatment with RNS60. The bar graph represents mean ± SEM as a percentage versus NTG (n = 3 mice
per group). All data were statistically analyzed using one-way ANOVA followed by post hoc Fisher’s LSD. **p < 0.01, ***p < 0.001
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C57BL/6-SOD1G93A mice compared to NTG was also
prevented in RNS60-treated mice although the latter
was not significant due to high variability of the data
(Fig. 4p).
RNS60 protects Schwann cells in the sciatic nerves of
C57BL/6-SOD1G93A mice
Alterations of Schwann cells and consequent demyelin-
ation of peripheral nerves have been implicated in the
Fig. 4 RNS60 activates astrocytes and phagocytic microglia and increases anti-inflammatory molecules in C57BL/6-SOD1G93A mice. a–c
Representative images of ventral LSC hemisections stained with GFAP (green) at 20 weeks. Scale bar: 50 μm. d Quantification of GFAP
immunofluorescence showed elevated astrocytosis in the LSC ventral horn of C57BL/6-SOD1G93A mice at the symptomatic stage of the
pathology as compared to NTG expressed as 100%. Treatment with RNS60 significantly increased reactive astrocytosis. Bars are mean ±
SEM as a percentage versus NTG controls (n = 3 animals for each group). e–g IBA1-stained (light blue) LSC hemisection from NTG, and
SOD1G93A mice treated with NS or RNS60. Scale bar: 50 μm. h Relative quantification showed higher level of IBA1 immunofluorescence
in transgenic mice compared to NTG, without changes after the treatment with RNS60. Data are expressed as mean ± SEM as percentage
versus NTG (n = 3 animals for each group). i–k CD68 positive macrophagic microglia (red) was labeled in ventral horn of LSC. Scale bar:
50 μm. l Immunoreactivity quantification showed an up-regulation of CD68 in the LSC of C57BL/6-SOD1G93A mice compared to NTG.
This effect was exacerbated by the treatment with RNS60. The bar graph represents mean ± SEM as a percentage versus NTG controls
(n = 3 mice per group). m–p Real-time PCR for pro-inflammatory (CCL2 and IL-1β) and anti-inflammatory (IL-4 and YM1) markers in the
ventral portion of LSC of NTG mice expressed as 100% and transgenic mice treated with NS or RNS60. For CCL2 (p = 0.7516 SOD1G93A
RNS60 vs SOD1G93A NS) and IL-1β (p = 0.7033 SOD1G93A RNS60 vs SOD1G93A NS) the increase observed in C57BL/6-SOD1G93A mice treated
with NS was unchanged by RNS60 treatment. On the contrary, as regard the anti-inflammatory markers such as IL-4 (p = 0.0033 SOD1G93A
RNS60 vs SOD1G93A NS) and YM1 (p = 0.2861 SOD1G93A RNS60 vs SOD1G93A NS), we observed a clear increase in RNS60 treated mice
suggesting an anti-inflammatory response, even if the increase of YM1 did not reach statistical significance. Data are normalized to
β-actin and expressed as the mean ± SEM fold change ratio between the two transgenic mice groups as percentage versus NTG
(n = 5 mice per group). All data were statistically analyzed using one-way ANOVA followed by post hoc Fisher’s LSD. *p < 0.05, **p < 0.01,
***p < 0.001, n.s. = non-significant
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disease progression in SOD1G93A mice [19]. Since it has
been demonstrated that RNS60 prevented loss of myelin
in EAE mice and promoted survival, maturation, and
expression of various myelin forming genes by oligoden-
drocytes in culture [30–32], we examined whether it
may also promote myelin maintenance in the sciatic
nerves of C57BL/6-SOD1G93A mice. Figure 5a, b shows
that the levels of CNPase, a myelin-associated enzyme,
which is markedly reduced in the sciatic nerves of
C57BL/6-SOD1G93A mice treated with NS compared to
NTG littermates, were completely restored by the treat-
ment with RNS60. However, the reduction of myelin
basic protein (MBP) levels in C57BL/6-SOD1G93A mice
was only modestly and not significantly attenuated by
the treatment with RNS60 (Fig. 5c, d).
RNS60 inhibits NMJ denervation and increases
macrophage infiltration in tibialis anterior muscle
We recently demonstrated that neuromuscular denerv-
ation, more than motor neuron loss, contributes to an
aggressive disease phenotype in SOD1G93A mice [19, 20, 46].
Therefore, we examined the effect of RNS60 on the level of
NMJ denervation in tibialis anterior muscle (TAM) sections
from 20-week-old C57BL/6-SOD1G93A mice using immuno-
reactivity for synaptophysin and bungarotoxin as pre-
synaptic and post-synaptic terminal markers respectively
(Fig. 6a–c). The numbers of denervated plaques in mice
treated with either NS or RNS60 were calculated as percent-
age of those found in NTG littermates. As shown in Fig. 6d,
the number of denervated plaques in mice treated with
RNS60 was slightly but significantly lower compared to those
of NS-treated mice. We also investigated the level of macro-
phage infiltration in the muscles which plays a role in modu-
lating the muscle reinnervation [47]. We observed an
increased immune staining for CD68 in C57BL/6-SOD1G93A
mice treated with NS compared with NTG littermates and
this effect was exacerbated by the treatment with RNS60
(Fig. 6e–h).
RNS60 reduces oxidative damage and increases
anti-oxidant response in the lumbar spinal cord
Oxidative stress associated with mitochondrial dysfunction
is a primary cause of neurodegeneration in ALS. In particu-
lar nitrosative stress, due to peroxynitrite-mediated tyrosine
nitration contributes to the irreversible protein damage [48].
Nitrotyrosine (NT) is a marker of this aberrant process in
ALS patients as well as in ALS mouse models [41].
Since putative mechanisms of RNS60’s action include
induction of mitochondrial biogenesis [49] and the in-
hibition of NO production from activated microglia
[22], we examined its effect on the levels of NT in
the ventral lumbar spinal cord of C57BL/6-SOD1G93A
Fig. 5 RNS60 preserves myelin maintenance in sciatic nerves of C57BL/6-SOD1G93A mice. a–d Representative immunoblots of the typical myelin
markers CNPase (a) and MBP (c) in sciatic nerve extracts from NTG and C57BL/6-SOD1G93A mice treated with NS or RNS60 at symptomatic stage
of the disease (140 days). b–d Densitometric analysis revealed a marked reduction of both CNPase and MBP in transgenic mice with respect to
NTG. The treatment with RNS60 completely prevented the reduction of CNPase and slightly, but non-significantly (p = 0.332), counteracted the
decrease of MBP. Data are reported as mean ± SEM of percentage vs NTG (n = 5 animals per group). Statistical analysis was performed using
one-way ANOVA followed by post hoc Fisher’s LSD. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = non significant
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mice. We found that the levels of NT were signifi-
cantly reduced in mice treated with RNS60 compared
to those treated with NS (Fig. 7a, b). Interestingly,
when we examined the levels of nuclear erythroid 2-
related factor 2 (Nrf2), a key mediator of the anti-
oxidant response Nrf2 was observed to be reduced in
the spinal cord of NS treated C57BL/6-SOD1G93A
mice compared to NTG mice and the loss was signifi-
cantly counteracted by treatment with RNS60 (Fig. 7c, d).
RNS60 stimulates the activation of the PI3K-Akt pro-
survival pathway in spinal cord and sciatic nerves
To investigate the possible mechanism through which
RNS60 protects MNs and NMJs in C57BL/6-SOD1G93A
mice, we examined the activation of the Akt pro-survival
pathway by Western blot analysis of the ventral horn of
lumbar spinal cord and sciatic nerves using an antibody
specific for Akt phosphorylated at Ser473. Levels of
activated, phosphorylated Akt (p-Akt) were found to be
significantly increased in the spinal cord of C57BL/6-
SOD1G93A mice compared to NTG mice, and this effect
was further increased by the treatment with RNS60
(Fig. 8a, b). Similarly, the levels of glycogen synthase kin-
ase 3beta (GSK3β) phosphorylated at Ser 9, a substrate of ac-
tivated Akt [50], were also found to be significantly increased
in C57BL/6-SOD1G93A mice treated with RNS60 compared
to those treated with NS (Fig. 8c, d). Interestingly, analyzing
the p-Akt distribution by immunohistochemistry in the ven-
tral of horn spinal cord, we observed a partial co-localization
of p-Akt with GFAP reactive astrocytes in SOD1G93A mice
compared to NTG mice (Fig. 8e, f) and this phenomenon
was exacerbated in the reactive astrocytes of RNS60 treated
(Fig. 8g, arrows) compared to NS-treated SOD1G93A mice.
The percent of astrocytes labeled with p-Akt over the total
number of GFAP-positive cells in the hemisection of ventral
horn of lumbar spinal cord were 9.8 ± 1.3 and 17.6 ± 2.0
(mean ± SEM; p < 0.05) in NS- and RNS60-treated mice, re-
spectively. In addition, most of these labeled astrocytes
showed a round-shaped morphology with little or no ramifi-
cation. In C57BL/6-SOD1G93A mice treated with RNS60, we
also found some CD68-positive microglial cells co-localized
with p-Akt (Fig. 8j, arrow), while this phenomenon was not
detected in SOD1G93A mice treated with NS (Fig. 8i). Some
surviving MNs were also markedly labeled for p-Akt (data
not shown).
Unlike in the spinal cord, we observed that the levels
of p-Akt were significantly reduced in sciatic nerves of
C57BL/6-SOD1G93A mice compared to NTG, and this
effect was also partially rescued by the treatment with
RNS60 (Fig. 8k, l).
RNS60 enhances the Treg population in the spleen of
SOD1G93A mice but not in the lumbar spinal cord
Emerging evidence suggests that low levels of regula-
tory T lymphocytes (Tregs) are responsible for ALS
disease progression in patients and mice [12, 18, 51].
Since RNS60 was reported to inhibit the disease
Fig. 6 RNS60 reduces NMJ denervation and promotes macrophage recruitment in TAM of C57BL/6-SOD1G93A mice. a–c Representative confocal
images of co-localization of synaptophysin (SYN, green) with bungarotoxin (BTX, red) in TAM of NTG mice and C57BL/6-SOD1G93A mice treated
with NS or RNS60 (scale bar 50 μm). d Denervation of NMJ was higher in TAM of transgenic mice treated with NS as compared to NTG (61.8 ±
2.8% vs. 22.3 ± 2.75). Treatment with RNS60 slightly but significantly reduced this percentage (52.4 ± 2.5%). Data are expressed as mean ± SEM,
(n = 5 animals per group). e–g Representative images of TAM of NTG, SOD1G93A NS and SOD1G93A RNS60 stained for CD68 (green), scale bar:
50 μm. Inserts show CD68+ cell infiltration at the level of NMJ labeled with bungarotoxin (red) at higher magnification, scale bar: 10 μm. h The
quantification of immunoreactivity showed an increase of CD68+ cells in transgenic mice treated with NS compared to NTG. The treatment with
RNS60 exacerbated the recruitment of macrophages. Data are expressed as mean ± SEM, (n = 5 animals per group). All data were statistically
analysized using one-way ANOVA followed by post hoc Fisher’s LSD, *p < 0.05, **p < 0.01, ***p < 0.001
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progression in EAE mice by increasing the Treg
population [30, 31], we examined the proportions of
Tregs both in the spinal cord and in the spleen, the
peripheral source of these cells, in SOD1G93A mice.
Treg levels were assessed by measuring transcript ex-
pression levels of specific markers of these cells,
FoxP3 and CD4, using real-time PCR. The treatment
with RNS60 significantly increased the levels of CD4
and prevented the significant decrease of FoxP3
mRNA found in the spleen of SOD1G93A mice treated
with NS with respect to NTG littermates (Fig. 9a, b).
In the spinal cord, however, we observed only non-
significant changes of CD4 and FoxP3 mRNA in the C57BL/
6-SOD1G93A mice compared to NTG littermates, and the
levels were not affected by RNS60 treatment (Fig. 9c, d,).
RNS60 neither ameliorates disease progression nor
protects MNs in 129Sv-SOD1G93A mice
Recently, we characterized a variant of the SOD1G93A
mouse model (129Sv-SOD1G93A) expressing the same
amount of mutant hSOD1 but showing an earlier onset
and a more rapid disease progression compared to
C57BL/6-SOD1G93A mice [20, 21, 46]. Among the fea-
tures that differentiate the two mouse models, we found
a massive downregulation of mitochondria-related tran-
scripts, decreased ATP levels and a lower activation of
immune response-related molecules in the motor neu-
rons of 129Sv-SOD1G93A mice [21]. This was associated
with an earlier and stronger NMJ denervation and with
a poor activation of immune cells in the sciatic nerves
and muscles compared to C57BL/6-SOD1G93A mice
[19]. To further test the therapeutic mechanism of
RNS60, we investigated its effect on the disease onset of
129Sv-SOD1G93A mice (Fig. 10a) as well as on the MNs
count (Fig. 10b), NMJs denervation (Fig. 10c), and acti-
vation of peripheral macrophage response (Fig. 10d).
Interestingly, no differences were observed between
RNS60 and NS treatment in 129Sv-SOD1G93A mice in
any of the parameters analyzed. On the contrary, in the
spinal cord, unlike in C57BL/6-SOD1G93A mice, we
found reduced levels of GFAP and no difference in the
upregulation of CD68 in response to RNS60 treatment
compared to NS (Fig. 10e, f ).
Discussion
The current work demonstrates, for the first time,
therapeutic effects of RNS60 in cellular and animal
models of ALS. RNS60 is a novel experimental drug
that contains charge-stabilized nanostructures consist-
ing of an oxygen nanobubble core surrounded by an
electrical double-layer at the liquid/gas interface. The
biological effects of RNS60 have been attributed to the
Fig. 7 RNS60 increases anti-oxidant response and reduces oxidative stress in the lumbar spinal cord of C57BL/6-SOD1G93A mice. Representative
dot-blot (NT) or immunoblots (Nrf2) and relative quantification performed on the ventral portion of LSC of NTG mice or transgenic C57BL/6-
SOD1G93A mice treated with NS or RNS60, at 20 weeks of age. a, b The levels of NT are increased in C57BL/6-SOD1G93A mice treated with NS
compared to NTG mice, whereas they are similar to NTG in mice treated with RNS60. c, d While the levels of Nrf2 are reduced in C57BL/6-
SOD1G93A mice treated with NS compared to NTG mice, the treatment with RNS60 prevented this reduction. Data are expressed as mean ± SEM,
(n = 5 animals per group). All data were statistically analyzed using one-way ANOVA followed by post hoc Fisher’s LSD. *p < 0.05, **p < 0.01,
***p < 0.001, n.s. = non significant
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physical properties of the charge-stabilized nanostructures
as ONS60, a control solution containing levels of oxygen
comparable with RNS60 (50 to 60 ppm) but not subjected
to TCP flow had not been effective in several earlier
studies [22, 24–26]. We confirmed this observation in the
model of motor neuron/glia co-cultures exposed to LPS
(Additional file 1: Figure S1).
RNS60’s putative mechanism of action encompasses
the activation of pro-survival pathways, increase in
mitochondrial biogenesis, myelin maintenance and re-
pair, reduction of inflammation, and increase of Tregs
[22–32]. The current work demonstrates that RNS60
has a beneficial effect in cellular and animal models of
ALS presumably through the same mechanisms of ac-
tion (Fig. 11).
Initially, we found that RNS60 partially protects the
motor neuron damage induced by LPS-activated microglia,
suggesting an anti-inflammatory property of this potential
Fig. 8 RNS60 activates the p-Akt pro-survival pathway in the LSC and sciatic nerves of C57BL/6-SOD1G93A mice. a, b Representative immunoblots
performed on the ventral portion of LSC of NTG mice or transgenic C57BL/6-SOD1G93A mice treated with NS or RNS60, at 20 weeks of age, and
relative quantification. There was an increase of Akt phosphorylation (at Ser473) in RNS60 treated mice compared to NS treated mice. This was
paralleled by increased phosphorylation of GSK3β at Ser9 (c, d), one of the downstream targets of activated Akt. e–g Representative images of
the co-localization of p-Akt and GFAP immunostaining. P-Akt (red) was highly expressed specifically in the MNs of NTG mice (e). In SOD1G93A mice
treated with NS, the number of p-Akt labeled MNs decreased while few of the highly reactive astrocytes (green) co-localized with p-Akt (f).
Colocalization of Akt and GFAP was exacerbated in the SOD1G93A mice treated with RNS60 (G, arrows). The inset in G show enlarged reactive
astrocytes expressing p-Akt and showing a spheroid or less ramified morphology (n = 3 animals per group). h–j Representative images of the
co-localization of p-Akt (red) and CD68 (green) immunostaining. In SOD1G93A mice treated with RNS60, few CD68-positive microglial cells
colocalized with p-Akt (arrow), while this phenomenon was not detected in SOD1G93A mice treated with vehicle (i). The inset in J show enlarged
macrophagic-microglial cells expressing p-Akt (n = 3 animals per group). k, l Decreased levels of Ser473 Akt phosphorylation were found in the
sciatic nerves of SOD1G93A mice treated with NS but not in RNS60 treated mice compared to NTG. Bar graphs represents mean ± SEM as a
percentage versus NTG controls (n = 5 animals per group). All data were statistically analyzed using one-way ANOVA followed by post hoc
Fisher’s LSD. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significant
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therapeutic. This is consistent with previous studies show-
ing that RNS60 suppressed the LPS-induced expression of
iNOS in microglia [22]. Next, we demonstrated that RNS60
protected motor neurons (MN) in astrocytes-spinal neu-
rons co-cultures carrying the SOD1G93A mutation.
In addition, and most importantly, intraperitoneal treat-
ment of C57BL/6-SOD1G93A mice with RNS60 beginning
at the onset of disease symptoms resulted in significantly
improved outcome, which was characterized by protection
of motor neurons, a delay in the onset of neuromuscular
deficit and paralysis, and an increase of the mean survival
interval from onset. Neuroprotective effects of RNS60
treatment were seen previously in other models of neu-
roinflammatory diseases, in particular the MPTP mouse
model of PD [23]. The protective effects of RNS60 in this
model, as well as in the case of microglial iNOS expres-
sion and NF-kB activation by LPS in vitro [22], were
dependent on the activation of the class 1A PI3K-Akt
pathway, which has emerged as a central mechanism of
action of RNS60.
The effects seen in our study are likely mediated
through the same pathway based on the following obser-
vations. Using the experimental paradigm of the in vitro
experiments presented here, we have previously demon-
strated that MN death was counteracted by Akt
activation-induced motor neuron-specific overexpression
of MyrAKT3 [13]. Involvement of Akt is further
supported by the fact that RNS60 also preserved the
number and length of neurites, which is consistent with
a previous study reporting RNS60 to increase the num-
ber of neurites as well as the length, size, and maturation
of dendritic spines in primary hippocampal neurons
through the activation of the PI3K-Akt pathway [26].
The most direct evidence comes from the C57BL/6-
SOD1G93A mouse model, where we measured increased
phosphorylation of Akt in lumbar spinal cord and sciatic
nerves of mice treated with RNS60. Increased Akt phos-
phorylation was paralleled by phosphorylation (inactiva-
tion) of GSK3-β, further confirming the functional
activation of Akt. The activation of this pathway also has
Fig. 9 RNS60 augments Treg population in the spleen but not in LSC of C57BL/6-SOD1G93A mice. a, b Real-time PCR for typical markers of Treg
in spleen of SOD1G93A mice expressed as 100% and transgenic mice treated with NS or RNS60. Treatment with RNS60 completely reverted the
decrease of FoxP3 found in the spleen of SOD1G93A NS mice compared to NTG mice and markedly increased the levels of CD4+ T cells with
respect to both the SOD1G93A NS and NTG mice. c, d On the contrary, we did not observe a significant difference for both markers between the
two groups of transgenic mice in the LSC. Data are normalized to β-actin and expressed as the mean ± SEM change ratio between the two group
of transgenic mice as percentage versus NTG (n = 5 mice per group). All data were statistically analyzed using one-way ANOVA followed by post
hoc Fisher’s LSD. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = non-significant
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previously been linked to motor neuronal protection in
vivo. For example, we reported that the specific induc-
tion of Akt3 via lentiviral vector in motor neuron sus-
tained cell viability via inhibition of GSK3β
(phosphorylated at Ser9) [13]. Moreover, delivery of
insulin-like growth factor 1 (IGF-1) to SOD1G93A mice
through motor neuron-targeted viral vectors [15], or by
intrathecal infusion [52], partially protected motor neu-
rons and delayed disease progression via activation Akt
in the spinal cord. Similarly, intracerebroventricular
Fig. 10 RNS60 does not affect the disease progression and the pathology in 129Sv-SOD1G93A mice. Treatment with RNS60 or NS (300 μl/mouse/IP)
every other day started from the onset (91 days, hind limbs tremor and reduced abduction) until the symptomatic phase (112 days). a Kaplan-Meier
curve shows that the treatment with RNS60 does not modify the onset of muscle strength impairment in fast progressive mice. The curve was
evaluated by the Log-rank test, p = 0.1886 (n = 10 NS; n = 10 RNS60). b Quantification of motor neurons with cell body area > 400 μm2 in LSC. At
symptomatic stage of the disease, MNs decreased in both SOD1G93A groups of mice compared to NTG without any difference between the treatments.
The bar graphs represent mean ± SEM as percentage versus NTG controls (n = 5 animals per group). c Quantification of NMJ denervation in TAM. In
transgenic mice there is a higher percentage of denervated plaques compared to NTG. The treatment with RNS60 does not modify these numbers.
Data are expressed as mean ± SEM, (n = 5 animals per group). d Quantification of immunoreactivity showed an increase of CD68+ cells in transgenic
mice compared to NTG without any change by RNS60 treatment. Data are expressed as mean ± SEM, (n = 5 animals per group). e Quantification of
immunofluorescence showed elevated astrocytosis in the LSC ventral horn of 129Sv-SOD1G93A mice at the symptomatic stage of the pathology as
compared to NTG expressed as 100%. Treatment with RNS60 significantly decreases the reactive astrocytosis (p < 0.001 SOD1G93A RNS60 vs SOD1G93A
NS). f CD68 immunoreactivity quantification showed an up-regulation in the LSC of SOD1G93A mice compared to NTG. This effect was unchanged by
the treatment with RNS60. Bar graphs are mean ± SEM as percentage versus NTG (n = 5 animals for each group). All data were statistically analyzed
using one-way ANOVA followed by post hoc Fisher’s LSD. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. = non-significant
Vallarola et al. Journal of Neuroinflammation  (2018) 15:65 Page 16 of 22
injection of VEGF in SOD1G93A rats also improved
motor performance, prolonged survival, and raised
p-Akt levels in the spinal cord [17, 53].
Unexpectedly, in RNS60-treated C57BL/6-SOD1G93A
mice, higher level of p-Akt was present not only in
viable motor neurons but also by GFAP-positive reactive
astrocytes in the ventral horn of lumbar spinal cord at
the time when the motor neurons were protected, and
muscle paralysis was delayed. This may appear counter-
intuitive because reactive astrocytosis is considered a
hallmark of neuronal death. It has been demonstrated,
however, that not all astrocytes are intrinsically neuro-
toxic for motor neurons as the total ablation of prolifer-
ating astrocytes did not slow the disease progression and
motor neuron loss in SOD1 mutant mice [54]. Likewise,
a focal degeneration of astrocytes has been reported in
concomitance with the loss of motor neurons in
SOD1G93A mice, and their protection through metabo-
tropic GluR5 receptor inhibition significantly delayed
the onset of the disease [55]. These protective astrocytes
appeared as spheroid GFAP-positive cells that existed to-
gether with typical reactive astrocytes [55]. Interestingly,
many p-Akt-positive astrocytes in RNS60-treated mice
appeared with similar spheroid morphology. This sug-
gests that RNS60 may have prevented the degeneration
of these focal astrocytes through the activation of p-Akt,
thus promoting motor neuron survival. Since the level of
the astrocyte specific glutamate transporter 1 (GLT1), a
key factor in the control of excitotoxicity, is increased by
the activation of the Akt pathway [56], this could be a
potential mechanism for the MN protective effect of
RNS60. The exact mechanism by which RNS60 activates
Akt in astrocytes is presently unknown. Studies in vitro
have demonstrated that IGF1 is a potent activator of Akt
in astrocytes during oxidative stress and that this is a
key mechanism for IGF1 to induce neuroprotection
against oxidative stress injury [57]. Thus, it is possible
that even in the presence of the pro-oxidant SOD1G93A,
the activated astrocytes in the spinal cord of RNS60-
treated mice may acquire a neuroprotective function
through the activation of Akt. Whether this may be me-
diated by IGF1 or other factors needs to be investigated.
In addition to the increase of astrocytes, the number
of CD68-positive microglia in the spinal cord of RNS60-
treated C57BL/6-SOD1G93A mice was also increased.
CD68 is expressed on phagocytic cells that can adopt a
Fig. 11 Schematic view of the potential mechanisms by which RNS60 protect motor neurons and ameliorate the neuromuscular impairment in
ALS. In the motor neurons RNS60 activates the p-Akt mediated pro-survival pathway and prevents the decrease of Nrf2 mediated anti-oxidant
response while reducing the mitochondrial alterations (reduced vacuoles) and oxidative stress (NT). RNS60 also enhances phosphorylation of
p-Akt, and levels of Nrf2, in a subpopulation of protective astrocytes that lead to an overexpression of the IL-4. IL-4 then induces the polarization
of CD68 microglia toward a prohealing M2 phenotype creating a neuroprotective environment. In the sciatic nerve RNS60 prevents demyelination
by protecting Schwann cells through the p-Akt pro-survival pathway and this results in the reduced NMJ denervation. This, together with the
increased of CD68 positive macrophage recruitment in the muscle and the consequent debris clearing and tissue remodeling, results in the
amelioration of neuromuscular impairment. RNS60 may also exert its protective action through the activation of immunomodulatory Treg, known
to be negatively correlated with the severity of ALS in patients and animal models
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protective M2 phenotype in response to injection of
anti-inflammatory IL-4 [58]. Interestingly, we detected a
concomitant increase of IL-4 in the lumbar spinal cord
of RNS60-treated mice. In addition, the reduction of
Ym1, a marker of the M2 microglia phenotype in
SOD1G93A mice, was reverted by the treatment with
RNS60 while the pro-inflammatory cytokines IL-1β and
CCL2 remained unchanged. We also observed activation
of Akt in CD68-positive microglial cells only in RNS60-
treated mice. This is consistent with the observation that
the PI3K/Akt pathway and its downstream targets have
emerged as central regulators of M2 phenotype activa-
tion in macrophages/microglia [59]. For example, HDAC
inhibitors have been shown to polarize microglia toward
M2 by enhancing PI3K/Akt signaling in a model of se-
vere traumatic brain injury preventing white matter
damage [60]. Interestingly, Akt activation in macro-
phages was associated with reduced M1 markers and
disease severity in a mouse model of EAE [61].
The neuroprotective role of M2 microglia is still de-
bated but it seems that an increase of macrophagic activ-
ity in a specific phase of the disease may be associated
with debris clearing and tissue remodeling [62, 63]. This
process is particularly relevant at the level of the periph-
eral nervous system where immune cell infiltration may
promote the phagocytic activity of Schwann cells and
macrophages toward the degenerated axons to permit
functional nerve regeneration and NMJ innervations
[64–66]. We have recently demonstrated that the re-
cruitment of immune cells in the peripheral nervous sys-
tem delays muscle denervation and prolongs the lifespan
in C57BL/6-SOD1G93A mice [19]. Here, we found that
RNS60 increased macrophage recruitment in tibialis an-
terior muscle and this correlated with reduced NMJ
denervation.
Consistent with a protective role of immune cells,
129Sv-SOD1G93A mice showing a fast disease progres-
sion are less prone to recruit macrophages and T cells in
the peripheral sciatic nerve at the disease onset [20]. We
therefore hypothesize that RNS60’s ineffectiveness in
delaying onset and progression of muscular deficit and
motor neuron degeneration in 129Sv-SOD1G93A mice
was due to the lack of response to RNS60-induced activa-
tion of the protective immune response. This is consistent
with the lack of increase of CD68 immunoreactivity in the
muscle tibialis and spinal cord in these mice compared to
RNS60-treated C57BL/6 strain, and with a reduction of
GFAP immunoreactivity in the spinal cord compared to
NS-treated mice. This hypothesis is also in agreement
with the observation of a lower macrophage recruitment
in 129Sv mice, compared to C57BL/6 mice, after acute
spinal cord injury [67]. In addition, the lower immune re-
sponse in 129Sv mice is also reflected by the fact that
these mice, in contrast to C57BL/6 mice, are resistant to
EAE induced by myelin oligodendrocyte glycoprotein
(MOG) [68]. We recently demonstrated that the compari-
son of 129Sv-SOD1G93A and C57BL/6-SOD1G93A mouse
strains is useful to study disease susceptibility and to test
novel therapeutic approaches aimed at addressing disease
heterogeneity [69]. This may be relevant for the use of
RNS60 in clinical trials of ALS patient cohorts that show
heterogeneous disease severity. For example, a recent clin-
ical trial with edaravone showed efficacy only in a well-
defined group of patients [5]. A deeper biochemical and
molecular analysis of these two mouse models might help
to identify potential biomarkers to predict the positive or
negative response to treatment in clinical trials.
In further support of potential protective immuno-
modulatory mechanisms, RNS60 increased Tregs in the
spleen of C57BL/6-SOD1G93A mice. Tregs are increased
at early slow progressing stages of ALS and decreased
during the rapidly progressing phase both in mice and in
rapidly progressing ALS patients [18]. Passive transfer of
endogenous Treg from ALS mice in the early disease
stage into recipient ALS mice in a more progressed
stage, without ex vivo activation, were shown to sustain
IL-4 levels and M2 microglia, lengthen disease duration,
and prolong survival [14, 18, 70]. We observed increased
levels of IL-4 and a tendency to increase of the M2
microglia marker YM1 in the spinal cord of C57BL/6-
SOD1G93A mice treated with RNS60, despite the fact
that the expression levels of CD4 T cells and FoxP3 were
unchanged in this compartment. Thus, we hypothesize
that peripheral Treg may contribute to the protective ef-
fect of RNS60 through a possible action at the neuro-
muscular level; however, the mechanism involved needs
to be investigated.
Schwann cells are linked to the pathology in C57BL/6-
SOD1G93A mice and seem to contribute to the protective
action of RNS60. We found a significant downregulation
of p-Akt in the sciatic nerves of symptomatic C57BL/6-
SOD1G93A mice, which was associated with a marked
decrease of both CNPase and MBP. This supports the
prior finding of a key role of Akt in regulating the PNS
myelination, enhancing membrane wrapping and myelin
protein synthesis [71–75]. The downregulation of p-Akt,
CNPase, and MBP was inhibited or reverted by treat-
ment with RNS60. This is in line with the evidence that
RNS60 retained the expression of myelin genes and
blocked demyelination in CNS of EAE mice through the
promotion of oligodendrocyte survival and OPC differ-
entiation [30–32]. A more recent report showed a direct
transcriptional effect of RNS60 on expression of myelin-
related genes via the activation of PI3K-Akt-CREB [24].
RNS60 has been reported to modulate mitochondrial
bioenergetics. In oligodendrocytes subjected to meta-
bolic stress, RNS60 enhances the capacity of mitochon-
dria to produce ATP [32]. In a neuronal cell line,
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primary dopaminergic neurons, and in the nigra of
MPTP challenged mice, RNS60 was reported to upregu-
late mitochondrial biogenesis [49]. Alterations in the
structure and function of mitochondria are a typical trait
of ALS. In particular, the expression of mutant SOD1 is
causally linked to alteration in their motility, dynamics,
and turnover leading to energy deficit, calcium mishand-
ling, and oxidative stress, which are all key contributors
to motor neuron death [76]. In fact, it is known that mu-
tant SOD1 accumulates in the outer membrane of mito-
chondria and causes the swelling of these membranes
and consequent vacuole formation [43, 44, 77]. In sup-
port of an involvement of mitochondria in the effects of
RNS60 observed in this study, we found a reduction of
vacuoles immunostained for mutant hSOD1 in the
spinal cord of RNS60-treated C57BL/6-SOD1G93A mice
compared to the NS-treated mice. That the protective
effect of RNS60 could be partly mediated by action on
mitochondria is also indicated by the fact that RNS60 is
ineffective in 129Sv-SOD1G93A mice. In fact, the patho-
logical phenotype of these mice, unlike that of the
C57BL/6-SOD1G93A mice, is largely due to a marked
mitochondrial dysfunction that could render them unre-
sponsive to the protective action of RNS60.
How the mitochondrial effects of RNS60 are related to
the modulation of the PI3K-Akt pathway is unclear at
this time. Reports on RNS60-induced increased synaptic
transmission by upregulated mitochondrial ATP synthe-
sis in a squid giant synapse ex vivo model [27, 28] have
raised the notion that delivery of the oxygen contained
in the nanobubbles may directly feed into mitochondrial
ATP production [27]. Of note though, RNS60 has been
reported to increase mitochondrial biogenesis and ATP
generation in a neuronal cell line as well as in primary
dopaminergic neurons in a PI3K-dependent manner,
lending support to an Akt-mediated process [49]. In
other cell types, Akt has been shown to be involved in
the regulation of bioenergetics. In cultured hepatocytes,
for example, activated Akt translocates to the mitochon-
dria where it phosphorylates subunits of ATP synthase
and GSK3-β [78]. Akt-induced inhibition of GSK3-β in
turn leads to activation of the mitochondrial enzyme
pyruvate dehydrogenase (PDH), thereby boosting mito-
chondrial ATP production [78]. Further studies are
needed to address these details in neuronal cells and im-
mune cells and to determine whether a direct effect of
delivered oxygen, an indirect effect through PI3K-Akt
activation, or both are behind the increased mitochon-
drial ATP generation in response to RNS60.
Lastly, treatment with RNS60, an oxygen-containing
drug, did not seem to cause any additional oxidative
stress, and to the contrary, resulted signs of an anti-
oxidant effect. Nrf2 is a basic region leucine-zipper tran-
scription factor that binds to the antioxidant response
element (ARE) and activates a battery of genes involved in
the cellular antioxidant and anti-inflammatory defense, as
well as mitochondrial biogenesis [79]. Reduction of Nrf2
expression levels in motor neurons and astrocytes has
been demonstrated in ALS mouse models and patients
[21, 79] and is thought to contribute to chronic motor
neuron degeneration. In contrast, activation of Nrf2 is
neuroprotective in a mouse model of ALS [80]. Thus,
the prevention of Nrf2 reduction by RNS60 observed here
is likely tied to an anti-oxidant response that is associated
with its protective action on MNs. The reduction of NT
levels seen in RNS60-treated C57BL/6-SOD1G93A mice
supports this conclusion.
Conclusions
In summary, the present study demonstrated that intra-
peritoneal treatment with RNS60 starting from onset of
the disease delays the onset of neuromuscular deficit
and paralysis, and increases the survival interval from
onset in C57BL/6-SOD1G93A mice by about 17%. This
effect seems to be similar to or better than that obtained
with other treatments targeting neuroinflammation,
mitochondrial dysfunction, and oxidative stress [81], in-
cluding that of edaravone, an antioxidant which has
been recently approved by FDA for ALS treatment [82].
Notably RNS60, like edaravone, displayed a delay in
motor decline with a trend to survival extension when
the treatment started at the onset of symptoms. This is
important in light of the translation to clinical practice
where patients can only be treated at the diagnosis, often
after the symptom onset. Moreover, RNS60 has a simple
chemical composition (NaCl, oxygen, and water), which
reduces the likelihood of side effects caused by metabolic
by-products and may allow it to be safe when used in
combination with other compounds. These significant
preclinical findings, together with the excellent clinical
safety profile, make RNS60 a promising candidate for ALS
therapy and support further studies to unravel its thera-
peutic potential and molecular mechanism of action.
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Additional file 1: Figure S1. Primary microglia-MN enriched co-cultures
exposed to LPS for 24 h after 6 DIV. The bar graph indicates that LPS
reduces the viability of MNs treated with 10% (v/v) NS or ONS60 (ONS)
by about 30%. The toxic effect was significantly prevented by RNS60
(10% v/v). Data are expressed as mean ± SEM (n = 6), One-way ANOVA
(p < 0.001) followed by post hoc Fisher’s LSD. *** = p < 0.001.
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Additional file 2: Figure S2. Representative immunoblot for GFAP
performed on ventral portion of LSC of NTG mice or transgenic mice
treated with NS or RNS60, at 20 weeks of age, and relative quantification.
Data are expressed as mean ± SEM, (n = 5 animals per group). Data were
statistically analyzed using one way ANOVA followed by post hoc Fisher’s
LSD. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, n.s. = non significant.
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Additional file 3: Figure S3. A-D) Representative images of LSC
micrographs stained with S100β (green) and GFAP (red) at 20 weeks of
age. Scale bar: 20 μm. E) Quantification of immunofluorescence showed
no differences between the two transgenic groups. Bar graphs represents
mean ± SEM, (n = 5 animals per group); One-way ANOVA followed by
post hoc Fisher’s LSD non-parametric test (p = 0.420). (DOCX 1342 kb)
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